Business Wire

MINSTRY-SCINCE-ICT-FUTUR

Share
Innovative Korean Tech Startups Expand into the European Market

31 promising Korean startups are attending TNW Conference Europe 2017 (hereafter “the Conference”) to be held May 18-19, 2017, in Amsterdam, Netherlands.

31 Promising startups of Korea will showcase advanced technologies such as Fintech based on blockchain, nano new materials, eco-friendly products, IoT and software service to the European market.

Ministry of Science, ICT and Future Planning (hereafter “MSIP”), Ministry of Culture, Sports & Tourism and Small and Medium Business Administration of the Korean government are making joint efforts in backing tech startups to advance into the European market under the name of K-Startup.

Mr. Koh Kyeongmo, Deputy Minister for Creative Economy Coordination in MSIP showed high expectations for the Conference in that it will trigger promotion of Korean startups’ tech capabilities on the global stage and attract substantial investment in the future.

TNW Conference Europe 2017

This is the largest tech conference in Europe having been initiated from 2006 and it consists of programs including workshops, tailored networking events for startups and exhibitions. It is expected to attract about 20,000 participants and 4,000 companies who are tech investors, accelerators and startups from over 100 countries.

The Korean government will increase the support for Korean tech startups pioneering into the European market by utilizing the venue of the Conference.

Korea in TNW Conference

In the Conference, the Korean government is operating K-Startup Pavilion which displays products and services from various fields such as iris recognition devices and solutions, drones with one-handed controllers, seed packages and portable hydro-power generators.

In particular, the Korean government will cohost Investor Dinner with TNW, thereby fostering networking of global investors. In the venue, around 80 promising investors handpicked by TNW along with some Korean startups participate.

Furthermore, 7 Korean startups are advancing to the semi-final round of competition which guarantees them the chance to pitch in Arena. In the competitions, Korean startups’ innovative products will be promoted and the startups will compete to be award-winners.

31 Promising Startups of Korea

Major Korean startups will take part in the Conference. For example, Smart Study , a kids-content startup having exceeded 15.5m dollars in sales as of 2016 will attend the event. Studio XID , a software startup of which its service is used by global companies such as Google, Facebook, Baidu and Alipay will also participate. For detailed information on best Korean startups, please visit here or watch K-Startup Show reel.

Contact:

Ministry of Science, ICT and Future Planning
Yang Yunay, +82 2 2110 2086
Deputy Director
yunay@korea.kr

Link:

ClickThru

Social Media:

https://www.facebook.com/startup.go.kr/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release

Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian

1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release

In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new

Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release

Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye